Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Aug 19, 2021 1:27pm
83 Views
Post# 33731161

RE:RE:Good time to SELL!

RE:RE:Good time to SELL!Agreed.
She was built specifically for this role by working at Goodman's side all these years.
She does the day-to-day and makes it more efficient while drugs are added.
Her financial ability will we key in emerging markets.
Meanwhile, Goodman worries about the strategic developments.
Together ... they make it happen !

Early days are a bich but that is totally expected with this one.

Just a reminder, Goodman started his first company in 1996 and had a foot in emerging markets by 2010.  They had minority ownership of Pharmaplan 14 years in.  We have 100% ownship in North America (x-USA) in 7+ years.

That's one way of looking at - and - a fairly important one for certain key investors.

Not trying to get you to buy shares - sharing how I've been looking at this investment all along.

---------------

Paladin makes first step into emerging markets with 35% ownership of Pharmaplan:

https://www.biospace.com/article/releases/paladin-labs-inc-makes-first-step-into-emerging-markets-through-strategic-investment-in-b-pharmaplan-b-/

2 years later ... swapped it out in a deal for 45% ownership in Litha/Parmaplan (also in South Africa):

https://www.theglobeandmail.com/globe-investor/paladin-labs-to-buy-45-stake-in-south-africas-litha/article547654/







Snowballgrowth wrote:
indoubtgetout wrote: New CEO is the same as the old CEO - pathetic!!   Good time to GTFO!!


I think she will be a very good CEO. Well desserve. 



<< Previous
Bullboard Posts
Next >>